Addressing the medicines access challenge through balance, evidence, collaboration and transparency: key take-away lessons of the 4th PPRI Conference

Addressing the medicines access challenge through balance, evidence, collaboration and transparency: key take-away lessons of the 4th PPRI Conference

The 4th PPRI Conference, held in Vienna in October 2019, addressed issues related to equitable and affordable access to medicines. A multi-stakeholder audience from around the globe discussed solutions and best practice models for current challenges such as high-priced medicines, limitations of curr...

Full description

Bibliographic Details
Main Authors:	Sabine Vogler, Nina Zimmermann, Zaheer-Ud-Din Babar, Reinhard Busse, Jaime Espin, Aukje K. Mantel-Teeuwisse, Dimitra Panteli, Fatima Suleman, Veronika J. Wirtz
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2021-12-01
Series:	Journal of Pharmaceutical Policy and Practice
Subjects:	access to medicines policy options affordability pricing policies reimbursement medicine prices debate collaboration
Online Access:	http://dx.doi.org/10.1186/s40545-021-00300-3

Similar Items

Reimbursement measures in European countries – findings of a bibliometric literature review
by: Sabine Vogler, et al.
Published: (2015-12-01)

Assessing the prices and affordability of oncology medicines for three common cancers within the private sector of South Africa
by: Phyllis Ocran Mattila, et al.
Published: (2021-07-01)

Pharmaceutical pricing policy in Greece: towards a different path.
by: Kyriakos Souliotis, et al.
Published: (2016-08-01)

Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview
by: Naina R. Verghese, et al.
Published: (2019-01-01)

Pre-approval incentives to promote adoption of personalized medicine: a theoretical approach
by: F. Antoñanzas, et al.
Published: (2019-10-01)

Adoption of the governmental affordable medicines programme by ukrainians.
by: M. V. Shevchenko, et al.
Published: (2020-07-01)

Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
by: Karolina Badora, et al.
Published: (2017-01-01)

How large are the differences between originator and generic prices? Analysis of five molecules in 16 European countries
by: Sabine Vogler
Published: (2012-12-01)

Pharmaceutical pricing and reimbursement policies: perspectives for the future
by: Andrew L Gray
Published: (2015-12-01)

Affordable and equitable access to subsidised outpatient medicines? Analysis of co-payments under the Additional Drug Package in Kyrgyzstan
by: Sabine Vogler, et al.
Published: (2019-06-01)

The timelines for the price and reimbursement authorization in Italy 2018–2020
by: Valentina Gallo, et al.
Published: (2022-12-01)

Implementation of Medicines Pricing Policies in Ghana: The Interplay of Policy Content, Actors’ Participation, and Context
by: Augustina Koduah, et al.
Published: (2023-12-01)

Testing the price and affordability of healthy and current (unhealthy) diets and the potential impacts of policy change in Australia
by: Amanda J. Lee, et al.
Published: (2016-04-01)

Association between medicine Price declaration by pharmaceutical industries and retail prices in Malaysia’s private healthcare sector
by: Nur Sufiza Ahmad, et al.
Published: (2019-12-01)

Drug pricing and reimbursement decision making systems in Mongolia
by: Gereltuya Dorj, et al.
Published: (2017-12-01)

Multi stakeholders of health and industries perspectives on medicine price transparency initiative in private health care settings in Malaysia
by: Nur Sufiza Ahmad, et al.
Published: (2020-07-01)

Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries
by: Juan Carlos Rejon-Parrilla, et al.
Published: (2023-11-01)

Evaluating Price and Availability of Essential Medicines in China: A Mixed Cross-Sectional and Longitudinal Study
by: Caijun Yang, et al.
Published: (2020-11-01)

A tale of two cities: the cost, price-differential and affordability of current and healthy diets in Sydney and Canberra, Australia
by: Amanda J. Lee, et al.
Published: (2020-06-01)

Healthy diets ASAP – Australian Standardised Affordability and Pricing methods protocol
by: Amanda J Lee, et al.
Published: (2018-09-01)

Policy options to deal with high-cost medicines – survey with European policy-makers
by: Nina Zimmermann, et al.
Published: (2015-12-01)

The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis
by: Xuejing Rong, et al.
Published: (2020-04-01)

Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis
by: R. Moodley, et al.
Published: (2019-08-01)

Availability, prices and affordability of selected essential medicines in Jordan: a national survey
by: Qais Alefan, et al.
Published: (2018-10-01)

Availability, price, and affordability of WHO priority maternal and child health medicine in public health facilities of Dessie, north-East Ethiopia
by: Abel Demerew Hailu, et al.
Published: (2020-09-01)

Accessibility of Essential Medicines for Children in Sichuan Province of China: A Cross-Sectional Study
by: Zhe Chen, et al.
Published: (2022-02-01)

Availability, Affordability, Access, and Pricing of Anti-cancer Medicines in Low- and Middle-Income Countries: A Systematic Review of Literature
by: Phyllis Ocran Mattila, et al.
Published: (2021-04-01)

Price variation among different brands of anticancer medicines available in hospital pharmacies of Nepal
by: Sunil Shrestha, et al.
Published: (2020-12-01)

Retail pharmacy prescription medicines’ availability, prices and affordability in Eswatini
by: Garikai Shambira, et al.
Published: (2021-09-01)

Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis
by: Kyung-Bok Son
Published: (2020-10-01)

Regenerative Medicine in South Korea: Bridging the Gap Between Authorization and Reimbursement
by: Dong-Sook Kim, et al.
Published: (2021-08-01)

Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon
by: N. Abdel Rida, et al.
Published: (2019-12-01)

A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges
by: Patricia Vella Bonanno, et al.
Published: (2021-11-01)

Retrospective analysis of prescriptions for the treatment of cardiovascular diseases in the program «Affordable medicines» on the example of a pharmacy
by: V. S. Huz, et al.
Published: (2020-10-01)

Availability, prices, and affordability of selected essential cancer medicines in a middle-income country – the case of Mexico
by: Daniela Moye-Holz, et al.
Published: (2020-05-01)

Evaluation of Availability, Prices, and Affordability of Selected Essential Medicines in Balochistan, Pakistan
by: Murad Bibi, et al.
Published: (2022-07-01)

Forming a medicines pricing policy for low and middle-income countries (LMICs): the case for Pakistan
by: Zaheer-Ud-Din Babar
Published: (2022-12-01)

Scenarios for Dealing with the Nursing Services Tariff Setting Act Based on the Policy Analysis Triangle Model
by: Kamran Bagheri Lankarani, et al.
Published: (2021-08-01)

Are payers treating orphan drugs differently?
by: Joshua P. Cohen, et al.
Published: (2014-01-01)

Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria
by: Konstantin Tachkov, et al.
Published: (2021-01-01)